Seshadri Neervannan
Known title: Chief Operating OfficerCIK: 0001827584
Associated companies
Transaction History
| TARS | ▼ Sell | Open Market | 2,989 | $200K | 3/20/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 4,589 | $307K | 3/19/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 3,610 | $248K | 3/18/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 3,125 | $217K | 3/17/2026 | View on chart |
| TARS | ▲ Buy | Option Exercise | 26,287 | — | 3/15/2026 | View on chart |
| TARS | ▼ Sell | Open Market | 8,366 | $641K | 3/4/2026 | View on chart |
| TARS | ▼ Sell | Gift | 950 | $0 | 12/16/2025 | View on chart |
| TARS | ▼ Sell | Gift | 475 | $0 | 12/16/2025 | View on chart |
| TARS | ▼ Sell | Open Market | 2,435 | $122K | 3/20/2025 | View on chart |
| TARS | ▼ Sell | Open Market | 2,543 | $121K | 3/19/2025 | View on chart |
| TARS | ▼ Sell | Open Market | 2,605 | $121K | 3/18/2025 | View on chart |
| TARS | ▲ Buy | Option Exercise | 21,264 | — | 3/15/2025 | View on chart |
| TARS | ▼ Sell | Open Market | 4,879 | $149K | 3/18/2024 | View on chart |
| TARS | ▲ Buy | Option Exercise | 13,245 | — | 3/15/2024 | View on chart |
| TARS | ▼ Sell | Open Market | 390 | $5K | 3/23/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 379 | $5K | 3/22/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 372 | $5K | 3/21/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 380 | $5K | 3/20/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 360 | $5K | 3/17/2023 | View on chart |
| TARS | ▼ Sell | Open Market | 357 | $5K | 3/16/2023 | View on chart |
| TARS | ▲ Buy | Option Exercise | 5,097 | — | 3/15/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals
The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.
Tarsus Reports XDEMVY Revenue and Option‑Style Retina Deals. The article notes that Tarsus’s drug XDEMVY is now generating revenue to cover operating costs. It also explains that the company’s retina product deals are structured like options, potentially providing flexible upside. These developments may improve the company’s cash flow outlook and support future growth initiatives.